Ly6C(lo) monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy

Current anti-VEGF therapies for colorectal cancer (CRC) provide limited survival benefit, as tumors rapidly develop resistance to these agents. Here, we have uncovered an immunosuppressive role for nonclassical Ly6C(lo) monocytes that mediates resistance to anti-VEGFR2 treatment. We found that the c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Jung, Keehoon, Heishi, Takahiro, Khan, Omar F., Kowalski, Piotr S., Incio, Joao, Rahbari, Nuh N., Chung, Euiheon, Clark, Jeffrey W., Willett, Christopher G., Luster, Andrew D., Yun, Seok Hyun, Langer, Robert, Anderson, Daniel G., Padera, Timothy P., Jain, Rakesh K., Fukumura, Dai
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5531423/
https://ncbi.nlm.nih.gov/pubmed/28691930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI93182
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados